SAN DIEGO, Dec. 19, 2013 – ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today that Mark G. Foletta has been appointed to its Board of Directors. Mr. Foletta is a seasoned financial executive with over 30 yearsof corporate experience. He was most recently senior vice president and Chief Financial Officer at Amylin Pharmaceuticals, Inc. He joined Amylin in 2000 and served through its acquisition by Bristol-Myers Squibb forapproximately $7 billion in August 2012. During his time at Amylin the company grew from 75 to over 1,300 employees and he was instrumental leading numerous strategic transactions with global pharmaceutical companies, as well as public and private financing transactions. As chair of Amylin’s Operating Committee, he had responsibility for business planning, forecasting and assessing performance. He also participated in the commercial launch of three novel pharmaceutical products that generated annual revenues reaching over $700M. Prior to Amylin, Mr. Foletta worked 14 years at Intermark, Inc./Triton Group Ltd. where he served as senior vice president,Chief Financial Officer and Corporate Secretary.
Read more: http://viacyte.com/press-releases/viacyte-appoints-mark-foletta-former-cfo-of-amylin-to-its-board-of-directors/
Via ViaCyte: Comments are closed.
|
Archives
October 2023
|